...
首页> 外文期刊>Free Radical Biology and Medicine: The Official Journal of the Oxygen Society >Exosomal biomarkers in Down syndrome and Alzheimer's disease
【24h】

Exosomal biomarkers in Down syndrome and Alzheimer's disease

机译:外泌体生物标志物在唐氏综合征和阿尔茨海默病

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Abstract Every person with Down syndrome (DS) has the characteristic features of Alzheimer's disease (AD) neuropathology in their brain by the age of forty, and most go on to develop AD dementia. Since people with DS show highly variable levels of baseline function, it is often difficult to identify early signs of dementia in this population. The discovery of blood biomarkers predictive of dementia onset and/or progression in DS is critical for developing effective clinical diagnostics. Our recent studies show that neuron-derived exosomes, which are small extracellular vesicles secreted by most cells in the body, contain elevated levels of amyloid-beta peptides and phosphorylated-Tau that could indicate a preclinical AD phase in people with DS starting in childhood. We also found that the relative levels of these biomarkers were altered following dementia onset. Exosome release and signaling are dependent on cellular redox homeostasis as well as on inflammatory processes, and exosomes may be involved in the immune response, suggesting a dual role as both triggers of inflammation in the brain and propagators of inflammatory signals between brain regions. Based on recently reported connections between inflammatory processes and exosome release, the elevated neuroinflammatory state observed in people with DS may affect exosomal AD biomarkers. Herein, we discuss findings from studies of people with DS, people with DS and AD (DS-AD), and mouse models of DS showing new connections between neuroinflammatory pathways, oxidative stress, exosomes, and exosome-mediated signaling, which may inform future AD diagnostics, preventions, and treatments in the DS population as well as in the general population. Graphical abstract Display Omitted Highlights ? Exosome technology can detect AD biomarkers decades prior to the onset of symptoms. ? Exosome signaling and release are affected by both oxidative homeostasis and inflammation. ? Exosomes may deliver therapies targeting oxidative stress, inflammation, and brain pathology.
机译:摘要患有综合症(DS)的每个人都有阿尔茨海默病(AD)神经病理学的特征特征,在其大脑中,由四十岁时,最多继续开发广告痴呆症。由于DS的人们显示出高度可变的基线功能水平,因此通常难以识别该人群中痴呆症的早期迹象。发现血液生物标志物预测DERMENIA发作和/或DS进展对于发展有效的临床诊断至关重要。我们最近的研究表明,神经元衍生的外来体是由体内大多数细胞分泌的小细胞外囊泡含有升高的淀粉样蛋白β肽和磷酸化 - Tau,其可以在儿童时期开始具有DS的人们中的临床前ad相。我们还发现,在痴呆症开始后,这些生物标志物的相对水平改变。外来释放和信号传导依赖于细胞氧化还原性稳态以及炎症过程,外来物质可能参与免疫应答,表明脑区脑区脑和炎症信号的炎症中炎症的触发器的双重作用。基于最近报道的炎症过程与外出释放之间的联系,DS人们观察到的升高的神经炎状态可能会影响外泌体AD生物标志物。在此,我们讨论从DS,DS和AD(DS-AD)的人们的研究的研究结果,以及DS的小鼠模型,显示神经引发途径,氧化应激,外来瘤和外出介导的信号传导之间的新连接,这可能会通知未来AD诊断,预防,DS人群以及一般人群中的治疗。图形抽象显示省略了亮点?外来技术可以在症状发作之前检测截止日期数十年。还外渗信号和释放受氧化稳态和炎症的影响。还外泌体可以递送靶向氧化应激,炎症和脑病理学的疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号